List of Tables
    Table 1. Postmenopausal Vaginal Atrophy Drugs CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
    Table 2. Postmenopausal Vaginal Atrophy Drugs Market Trends
    Table 3. Postmenopausal Vaginal Atrophy Drugs Market Drivers
    Table 4. Postmenopausal Vaginal Atrophy Drugs Market Challenges
    Table 5. Postmenopausal Vaginal Atrophy Drugs Market Restraints
    Table 6. Global Postmenopausal Vaginal Atrophy Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Postmenopausal Vaginal Atrophy Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Postmenopausal Vaginal Atrophy Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Postmenopausal Vaginal Atrophy Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Postmenopausal Vaginal Atrophy Drugs Manufacturers in Global Market, Ranking by Revenue (2021)
    Table 11. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturer, (US$ Million), 2017-2022
    Table 12. Global Postmenopausal Vaginal Atrophy Drugs Revenue Share by Manufacturer, 2017-2022
    Table 13. Global Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturer, (K Units), 2017-2022
    Table 14. Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Manufacturer, 2017-2022
    Table 15. Global Postmenopausal Vaginal Atrophy Drugs Price by Manufacturer (2017-2022) & (USD/Unit)
    Table 16. Global Postmenopausal Vaginal Atrophy Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 17. Global Postmenopausal Vaginal Atrophy Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Postmenopausal Vaginal Atrophy Drugs as of 2021)
    Table 18. Top Players of Postmenopausal Vaginal Atrophy Drugs in Global Market, Headquarters and Distribution of Producing Region
    Table 19. Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Type
    Table 20. Date of International Manufacturers Enter into Postmenopausal Vaginal Atrophy Drugs Market
    Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 22. Top Postmenopausal Vaginal Atrophy Drugs Players in United States Market, Ranking by Revenue (2021)
    Table 23. United States Postmenopausal Vaginal Atrophy Drugs Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 24. United States Postmenopausal Vaginal Atrophy Drugs Revenue Share by Players, 2020, 2021 & 2022
    Table 25. United States Postmenopausal Vaginal Atrophy Drugs Sales by Players, (K Units), 2020, 2021 & 2022
    Table 26. United States Postmenopausal Vaginal Atrophy Drugs Sales Share by Players, 2020, 2021 & 2022
    Table 27. Global Postmenopausal Vaginal Atrophy Drugs Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 28. Global Postmenopausal Vaginal Atrophy Drugs Sales in Volume by Region (2017-2022) & (K Units)
    Table 29. Global Postmenopausal Vaginal Atrophy Drugs Sales in Volume Forecast by Region (2023-2028) & (K Units)
    Table 30. Global Postmenopausal Vaginal Atrophy Drugs Sales in Value by Region (2017-2022) & (US$ Million)
    Table 31. Global Postmenopausal Vaginal Atrophy Drugs Sales in Value Forecast by Region (2023-2028) & (US$ Million)
    Table 32. North America Postmenopausal Vaginal Atrophy Drugs Sales in Volume by Country (2017-2028) & (K Units)
    Table 33. North America Postmenopausal Vaginal Atrophy Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 34. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales in Volume by Region (2017-2028) & (K Units)
    Table 35. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales in Value by Region (2017-2028) & (US$ Million)
    Table 36. Europe Postmenopausal Vaginal Atrophy Drugs Sales in Volume by Country (2017-2028) & (K Units)
    Table 37. Europe Postmenopausal Vaginal Atrophy Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 38. Latin America Postmenopausal Vaginal Atrophy Drugs Sales in Volume by Country (2017-2028) & (K Units)
    Table 39. Latin Americaa Postmenopausal Vaginal Atrophy Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 40. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales in Volume by Country (2017-2028) & (K Units)
    Table 41. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 42. Actavis plc Corporation Information
    Table 43. Actavis plc Description and Business Overview
    Table 44. Actavis plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 45. Actavis plc Postmenopausal Vaginal Atrophy Drugs Product
    Table 46. Actavis plc Recent Development
    Table 47. Bionovo, Inc. Corporation Information
    Table 48. Bionovo, Inc. Description and Business Overview
    Table 49. Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 50. Bionovo, Inc. Product
    Table 51. Bionovo, Inc. Recent Development
    Table 52. Endoceutics, Inc. Corporation Information
    Table 53. Endoceutics, Inc. Description and Business Overview
    Table 54. Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 55. Endoceutics, Inc. Product
    Table 56. Endoceutics, Inc. Recent Development
    Table 57. Novo Nordisk A/S Corporation Information
    Table 58. Novo Nordisk A/S Description and Business Overview
    Table 59. Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 60. Novo Nordisk A/S Product
    Table 61. Novo Nordisk A/S Recent Development
    Table 62. Pfizer Inc. Corporation Information
    Table 63. Pfizer Inc. Description and Business Overview
    Table 64. Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 65. Pfizer Inc. Product
    Table 66. Pfizer Inc. Recent Development
    Table 67. Teva Pharmaceuticals Ltd. Corporation Information
    Table 68. Teva Pharmaceuticals Ltd. Description and Business Overview
    Table 69. Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 70. Teva Pharmaceuticals Ltd. Product
    Table 71. Teva Pharmaceuticals Ltd. Recent Development
    Table 72. Therapeutics MD, Inc. Corporation Information
    Table 73. Therapeutics MD, Inc. Description and Business Overview
    Table 74. Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 75. Therapeutics MD, Inc. Product
    Table 76. Therapeutics MD, Inc. Recent Development
    Table 77. Shionogi & Company Corporation Information
    Table 78. Shionogi & Company Description and Business Overview
    Table 79. Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 80. Shionogi & Company Product
    Table 81. Shionogi & Company Recent Development
    Table 82. Allergan plc Corporation Information
    Table 83. Allergan plc Description and Business Overview
    Table 84. Allergan plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 85. Allergan plc Product
    Table 86. Allergan plc Recent Development
    Table 87. Shionogi & Co. Ltd. Corporation Information
    Table 88. Shionogi & Co. Ltd. Description and Business Overview
    Table 89. Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 90. Shionogi & Co. Ltd. Product
    Table 91. Shionogi & Co. Ltd. Recent Development
    Table 92. Key Raw Materials Lists
    Table 93. Raw Materials Key Suppliers Lists
    Table 94. Postmenopausal Vaginal Atrophy Drugs Customers List
    Table 95. Postmenopausal Vaginal Atrophy Drugs Distributors List
    Table 96. Research Programs/Design for This Report
    Table 97. Key Data Information from Secondary Sources
    Table 98. Key Data Information from Primary Sources
List of Figures
    Figure 1. Postmenopausal Vaginal Atrophy Drugs Product Picture
    Figure 2. Global Postmenopausal Vaginal Atrophy Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Postmenopausal Vaginal Atrophy Drugs Market Size 2017-2028 (US$ Million)
    Figure 4. Global Postmenopausal Vaginal Atrophy Drugs Sales 2017-2028 (K Units)
    Figure 5. United States Postmenopausal Vaginal Atrophy Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 6. United States Postmenopausal Vaginal Atrophy Drugs Market Size 2017-2028 (US$ Million)
    Figure 7. United States Postmenopausal Vaginal Atrophy Drugs Sales 2017-2028 (K Units)
    Figure 8. United States Postmenopausal Vaginal Atrophy Drugs Market Share in Global, in Value (US$ Million) 2017-2028
    Figure 9. United States Postmenopausal Vaginal Atrophy Drugs Market Share in Global, in Volume (K Units) 2017-2028
    Figure 10. Postmenopausal Vaginal Atrophy Drugs Report Years Considered
    Figure 11. Product Picture of Vaginal Gels
    Figure 12. Product Picture of Creams
    Figure 13. Product Picture of Tablets
    Figure 14. Product Picture of Rings
    Figure 15. Product Picture of Patches
    Figure 16. Global Postmenopausal Vaginal Atrophy Drugs Market Share by Type in 2022 & 2028
    Figure 17. Global Postmenopausal Vaginal Atrophy Drugs Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 18. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Type (2017-2028)
    Figure 19. Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2017-2028) & (K Units)
    Figure 20. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Type (2017-2028)
    Figure 21. Global Postmenopausal Vaginal Atrophy Drugs Price by Type (2017-2028) & (USD/Unit)
    Figure 22. United States Postmenopausal Vaginal Atrophy Drugs Market Share by Type in 2022 & 2028
    Figure 23. United States Postmenopausal Vaginal Atrophy Drugs Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 24. United States Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Type (2017-2028)
    Figure 25. United States Postmenopausal Vaginal Atrophy Drugs Sales by Type (2017-2028) & (K Units)
    Figure 26. United States Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Type (2017-2028)
    Figure 27. United States Postmenopausal Vaginal Atrophy Drugs Price by Type (2017-2028) & (USD/Unit)
    Figure 28. Product Picture of Offline Stores
    Figure 29. Product Picture of Online Stores
    Figure 30. Global Postmenopausal Vaginal Atrophy Drugs Market Share by Application in 2022 & 2028
    Figure 31. Global Postmenopausal Vaginal Atrophy Drugs Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 32. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Application (2017-2028)
    Figure 33. Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2017-2028) & (K Units)
    Figure 34. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Application (2017-2028)
    Figure 35. Global Postmenopausal Vaginal Atrophy Drugs Price by Application (2017-2028) & (USD/Unit)
    Figure 36. United States Postmenopausal Vaginal Atrophy Drugs Market Share by Application in 2022 & 2028
    Figure 37. United States Postmenopausal Vaginal Atrophy Drugs Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 38. United States Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Application (2017-2028)
    Figure 39. United States Postmenopausal Vaginal Atrophy Drugs Sales by Application (2017-2028) & (K Units)
    Figure 40. United States Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Application (2017-2028)
    Figure 41. United States Postmenopausal Vaginal Atrophy Drugs Price by Application (2017-2028) & (USD/Unit)
    Figure 42. North America Postmenopausal Vaginal Atrophy Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 43. North America Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 44. U.S. Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 45. Canada Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 46. Europe Postmenopausal Vaginal Atrophy Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 47. Europe Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 48. Germany Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 49. France Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 50. U.K. Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 51. Italy Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 52. Russia Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 53. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 54. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 55. China Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 56. Japan Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 57. South Korea Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 58. India Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 59. Australia Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 60. Taiwan Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 61. Indonesia Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 62. Thailand Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 63. Malaysia Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 64. Philippines Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 65. Latin America Postmenopausal Vaginal Atrophy Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 66. Latin America Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 67. Mexico Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 68. Brazil Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 69. Argentina Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 70. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 71. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 72. Turkey Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 73. Saudi Arabia Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 74. U.A.E Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 75. Postmenopausal Vaginal Atrophy Drugs Value Chain
    Figure 76. Postmenopausal Vaginal Atrophy Drugs Production Process
    Figure 77. Channels of Distribution
    Figure 78. Distributors Profiles
    Figure 79. Bottom-up and Top-down Approaches for This Report
    Figure 80. Data Triangulation
    Figure 81. Key Executives Interviewed